Thanks Bear, appreciated as always. It would be interesting to know which road the company would like to potentially take wrt some of these inflammatory diseases. As you said the choices might be straight to ph 3 with apabetalone or start at ph 1 with a new compound which might be more powerful. Each would seem to have advantages. Too bad management is not more efficient at partnering for some of these other conditions regardless of which route they choose to follow. I found it interesting that you mentioned that the new compounds might be available at RVX and/or Zenith. To me this speaks directly to the problem which I have spoken of before, two companies with shared management but materially different ownership may at some point be competitors and the lines that divide them seem to be regularly moving (as we've just witnessed again this week). In some ways this grey area might be the biggest drawback against investing in RVX and who knows how much this grey area effects the current share price.